Compare Degarelix (evidence A) and Gonadorelin (evidence A) on mechanism, clinical status, safety, and dosing.
Degarelix is a synthetic GnRH antagonist (MW ~1632.3 g/mol) and the first injectable GnRH receptor blocker approved for advanced prostate cancer. FDA-approved…
Gonadorelin is a synthetic decapeptide identical to the naturally occurring gonadotropin-releasing hormone (GnRH) produced in the hypothalamus. It stimulates…
Full profiles: Degarelix, Gonadorelin.